“We are incredibly excited to announce this well-deserved promotion. Jess was one of the early employees of the company and she has been instrumental in helping lead the organization through multiple phases of growth, including our initial public offering earlier this year. We look forward to her continued contributions,” said
Ms. Fees joined Surface in 2015, and has held roles of increasing responsibility, most recently as vice president, finance. She has over 20 years of experience in public and private accounting, audit, and corporate finance. Prior to Surface, she served as president of
ABOUT SURFACE ONCOLOGY:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response, and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies.
For more information, please visit www.surfaceoncology.com.
Ten Bridge Communications
Source: Surface Oncology, Inc.